

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 February 2023 (16.02.2023)



(10) International Publication Number
WO 2023/019203 A1

(51) International Patent Classification:

A61K 35/17 (2015.01) *A61P 37/06* (2006.01)
A61K 35/30 (2015.01) *C12N 5/079* (2010.01)
A61K 35/36 (2015.01) *C12N 5/071* (2010.01)
A61K 35/39 (2015.01) *C12N 5/0783* (2010.01)
A61K 35/44 (2015.01) *C12N 15/113* (2010.01)
A61K 35/55 (2015.01) *C07K 14/705* (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/074837

(22) International Filing Date:

11 August 2022 (11.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/232,141 11 August 2021 (11.08.2021) US
63/270,454 21 October 2021 (21.10.2021) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(71) Applicant: **SANA BIOTECHNOLOGY, INC.** [US/US];
188 East Blaine Street, Suite 400, Seattle, WA 98102 (US).

(72) Inventors: **DOWDLE, William**; 210 Eucalyptus Avenue,
South San Francisco, CA 94080 (US). **THAM, Eleonore**;
250 Vicksburg Street, Unit 3, San Francisco, CA 94114
(US). **RAMOS-ZAYAS, Rebeca**; 168 Adams Street, Unit
1, Waltham, MA 02453 (US). **SCHREPFER, Sonja**; 1
Tower Place, Suite 500, South San Francisco, CA 94080
(US).

(74) Agent: **MACDOUGALL, Christina, A.** et al.; Morgan,
Lewis & Bockius LLP, One Market, Spear Street Tower,
San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: INDUCIBLE SYSTEMS FOR ALTERING GENE EXPRESSION IN HYPOIMMUNOGENIC CELLS

(57) Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered cells and/or hypoimmunogenic stem cells, engineered cells and/or hypoimmunogenic cells differentiated therefrom, and/or engineered cells and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation comprising regulatable reduced expression of one or more MHC class I and/or MHC class II human leukocyte antigen molecules and regulatable overexpression of CD47. Provided herein are cells further exhibiting reduced expression of T-cell receptors.

WO 2023/019203 A1